Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Real world chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma: The Australian experience

View Full Paper
Ask AI
Bookmark
Share

Authors

SBSafia BelbachirMDMark R. DowlingMAMary Ann Anderson

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows 44% progression-free survival in patients with relapsed/refractory B-cell lymphoma, indicating potential for CAR-T therapy.

Key Points

  • The overall response rate to chimeric antigen receptor T-cell therapy at day 30 was 67%, with a complete response rate of 56%.
  • In a cohort undergoing leukapheresis, the median age was 67 years with a predominance of male patients at 89%.
  • This retrospective analysis evaluated outcomes from CD19-directed CAR-T therapy using Lugano criteria for lymphoma response.
  • Progression-free survival at one year was 44% and was associated with manageable toxicity like cytokine release syndrome in 60% of patients.

Cite This Study

Belbachir et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8fehttps://doi.org/10.1182/blood-2025-7246
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multi-centre real-world outcome of patients with Richter transformation receiving CD19-directed commercial CAR T-cell therapy in Australia.2025
  2. 2A simple scoring system for response and toxicity following lymphoma CAR-T: Results from the Australian CAR-T real-world consortium2025 · 1 citations
  3. 3Combining axicabtagene ciloleucel (axi-cel) or relmacabtagene autoleucel (relma-cel) with HDT/ASCT in relapsed/refractory large B-cell lymphoma: A single-center experience2025
  4. 4Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization2025 · 2 citations
  5. 5Real-world outcomes with CAR T-cell therapy for secondary central nervous system lymphoma are similar between patients with active versus historical involvement2025